Nadia Saoudi González (Nadia Saoudi Gonzalez)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Metastatic Colorectal Cancer

Epidermal Growth Factor Receptor

Monoclonal Antibody

Top Venues

Expert opinion on drug metabolism & toxicology

This page only lists publications with an associated author ORCID identifier.

Publications

Nadia Saoudi González, Javier Ros, Iosune Baraibar, Francesc Salvà, Marta Rodríguez-Castells, Adriana Alcaraz, Ariadna García, Josep Tabernero, Elena Élez
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer. Cancers 16 (2) (2024)
Nadia Saoudi González, Javier Ros, Iosune Baraibar, Francesc Salvà, Marta Rodríguez-Castells, Adriana Alcaraz, Ariadna García, Josep Tabernero, Elena Élez
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer. Cancers 16 (2) (2024)
Nadia Saoudi González, Daniel López, Diego Gómez, Javier Ros, Iosune Baraibar, Francesc Salva, Josep Tabernero, Elena Élez
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. Expert opinion on drug metabolism & toxicology (2022)
Nadia Saoudi González, Daniel López, Diego Gómez, Javier Ros, Iosune Baraibar, Francesc Salva, Josep Tabernero, Elena Élez
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. Expert opinion on drug metabolism & toxicology 18 (11) (2022)
Nadia Saoudi González, Daniel López, Diego Gómez, Javier Ros, Iosune Baraibar, Francesc Salva, Josep Tabernero, Elena Élez
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. Expert opinion on drug metabolism & toxicology 18 (11) (2022)
Nadia Saoudi González, Daniel López, Diego Gómez, Javier Ros, Iosune Baraibar, Francesc Salva, Josep Tabernero, Elena Élez
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. Expert opinion on drug metabolism & toxicology 18 (11) (2022)